Naproxen is an effective alternative to aspirin in the management of rheumatoid arthritis (Hill et al., 1974) . While salicylates remain the drug of choice as the initial treatment of childhood arthritis (Ansell, 1975) , in some patients they are either ineffective or not tolerated. Ibuprofen, given as a suspension, has been shown to be a possible alternative (Ansell, 1973) . When naproxen suspension became available preliminary studies showed it to produce satisfactory blood levels, with a half-life similar to that given by the tablets in adults, thus permitting a twice daily regimen .
The present study was undertaken to investigate the use of naproxen as Naprosyn Suspension in juvenile chronic polyarthritis. It consists of 2 parts, first, a comparative study with aspirin lasting 2 months, and, secondly, a tolerance study on the use of naproxen in the clinic.
Patients and methods

CROSS-OVER STUDY
Twenty-three patients entered a double-blind crossover study lasting eight weeks with two consecutive 4-week periods and random allocation for either naproxen or aspirin for the first period. All patients were suffering from seronegative juvenile chronic polyarthritis (Ansell and Bywaters, 1959) , and their disease was sufficiently active to be considered in need of an anti-inflammatory analgesic agent. The duration of the disease ranged from less than 1 year to 14 years, but in over half the patients it had lasted 2 years or less. The age of the patients was Accepted for publication 16 On entry to the trial 14 patients were receiving salicylates; of these 3 were also receiving ibuprofen and 4 indomethacin. Of the remaining 9, 3 had not received regular anti-inflammatory medication, 3 were on ibuprofen, 1 on ibuprofen with indomethacin, 1 on alclofenac, and 1 on benorylate. All these nonsteroidal anti-inflammatory drugs were discontinued after the initial assessment. Four patients were on maintenance gold, 2 on low-dose corticotrophin (Acthar gel), and 1 on penicillamine; these were continued unaltered throughout the study period. The dosages used were naproxen 10 mg per kg body weight per 24 hours given as a suspension in 2 divided doses, and soluble aspirin at 80 mg per kg per day given in 4 divided doses. Placebo suspension and tablets were given to make the study double-blind. (Table 3) . These patients were seen a few days early and were analysed as completing the trial. The physicians' assessment at the end of the study suggested that naproxen was better than aspirin in 9 patients, that both drugs were equal in 9 patients, while aspirin was better than naproxen in 5 patients (Table 4) . Difference not significant. Nineteen patients have completed 1 year of therapy without untoward side effects. One patient developed a rash and discontinued therapy at 1 month. One stopped at 9 months because of nausea and another at 11 months because of vomiting (Table 5) . At the dosage employed naproxen did not control the fever in 2 with serious systemic illness, 1 of whom subsequently had to have corticotrophin added to the regimen and ultimately has required penicillamine for continuing joint activity, with the other being controlled with indomethacin and high doses of aspirin.
Discussion
Naproxen at a dose of 10 mg per kg body weight was found to be as effective as soluble aspirin at Side effects were relatively infrequent and mild. As an 8-week comparison does not allow an adequate assessment of the tolerance and side effects of a new drug, a longer tolerance study was continued. This suggests that side effects do not become particularly obvious during a follow-up period up to 1 year. In both studies they were similar to those seen with adults, that is, gastrointestinal disturbances and rash. In the tolerance study naproxen did not control the fever of the 2 patients who had both systemic illness and arthritis.
